drugset

drugset / Trial / NCT01741727

A Study of ABT-414 in Subjects With Solid Tumors

NCT01741727 ↗

Phase 1 Completed 57 enrolled AbbVie

NaSingle-groupOpen-labelTreatment

Summary

A study of ABT-414 in subjects with solid tumors.

Timeline

Start: 2012-10
Primary completion: 2015-11
Completion: 2015-11

Publications

Results Munasinghe WP, Mittapalli RK, Li H, Hoffman DM, Holen KD, Menon RM, Xiong H. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR. Cancer Chemother Pharmacol. 2017 May;79(5):915-922. doi: 10.1007/s00280-017-3284-y. Epub 2017 Mar 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Depatuxizumab mafodotin	Other / unclassified	1 mg/kg	Intravenous
Subject	Depatuxizumab mafodotin	Other / unclassified	1.5 mg/kg	Intravenous
Subject	Depatuxizumab mafodotin	Other / unclassified	4 mg/kg	Intravenous

Indications